A Phase 2 interventional study of JTE-051 and Placebo in Plaque Psoriasis and Skin Diseases, sponsored by Akros Pharma Inc.. Terminated at 16 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-06.
Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 594th largest by enrollment of the 673 interventional ones that give a count, is one of 50 that started in 2017, is one of 200 in phase 2, and was the 465th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 50 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
This study is registered under Akros Pharma Inc., one of the names counted as Shionogi. Under that name alone:
Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Shionogi has 3 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
This study's enrollment of 13 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
First submitted before Akros Pharma Inc. became part of Shionogi.
Compared within Psoriasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: Placebo
Active drug tablets containing JTE-051
Placebo tablets identical in appearance to the active drug tablets
Proportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT).
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-75 response rate is defined as at least 75 percent (%) reduction in PASI score relative to Baseline.
Time frame: Up to 12 Weeks
Percent Change From Baseline in PASI Score
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percent change was calculated by taking the Week 12 PASI score and subtracting the baseline PASI, and dividing by the baseline PASI, then multiplying by 100 to get the percent change from baseline.
Time frame: Week 12
Proportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI)
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-50 response rate is defined as at least 50 percent (%) reduction in PASI score relative to Baseline.
Time frame: Week 12
Proportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI)
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-90 response rate is defined as at least 90 percent (%) reduction in PASI score relative to Baseline.
Time frame: Week 12
Proportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI)
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-100 response rate is defined as 100 percent (%) reduction in PASI score relative to Baseline.
Time frame: Week 12
Proportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1
The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). For this outcome measure, a score of 0 means no symptoms of psoriasis and a score of 1 means minimal symptoms of psoriasis.
Time frame: Week 12
Change From Baseline in Static Physician's Global Assessment (sPGA) Score
The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). Change from baseline to Week 12 in sPGA was calculated by taking the Week 12 sPGA and subtracting the baseline sPGA.
Time frame: Week 12
Percent Change From Baseline in Psoriasis Body Surface Area (BSA)
The total body surface area (BSA) affected by plaque-type psoriasis was obtained from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) and the resulting 4 values were added up to obtain the total psoriasis BSA (Range: 0 to 100). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region surface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs. Percent change from baseline to Week 12 in BSA was calculated by taking the Week 12 BSA and subtracting the baseline BSA, then dividing by the baseline BSA and multiplying by 100. A negative change from baseline at Week 12 indicates a reduction in the Psoriasis BSA compared to the baseline.
Time frame: Week 12
Change From Baseline in the Skindex-16 Overall Score
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Overall scale score is an average of 16 items expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Overall Score was calculated by taking the Week 12 Skindex-16 Overall Score and subtracting the baseline Skindex-16 Overall Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
Time frame: Week 12
Change From Baseline in the Skindex-16 Symptoms Scale Score
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score is an average of items 1 to 4 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Symptoms Scale Score was calculated by taking the Week 12 Skindex-16 Symptoms Scale Score and subtracting the baseline Skindex-16 Symptoms Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
Time frame: Week 12
Change From Baseline in the Skindex-16 Emotions Scale Score
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Emotions scale score is an average of items 5 to 11 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Emotions Scale Score was calculated by taking the Week 12 Skindex-16 Emotions Scale Score and subtracting the baseline Skindex-16 Emotions Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
Time frame: Week 12
Change From Baseline in the Skindex-16 Functioning Scale Score
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Functioning scale score is an average of items 12 to 16 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Functioning Scale Score was calculated by taking the Week 12 Skindex-16 Functioning Scale Score and subtracting the baseline Skindex-16 Functioning Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
Time frame: Week 12
Number of Subjects With Treatment-emergent Adverse Events
Subjects in the Safety Population (13, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The study was terminated early as per the Sponsor decision. All randomized subjects were included in the Safety Population.
Time frame: Up to 16 Weeks
JTE-051 Trough Plasma Concentrations
Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTE-051 in the subjects randomized to JTE-051 treatment groups.
Time frame: Week 12
Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.
| Milestone | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Started | 2 | 3 | 3 | 3 | 2 |
| Completed | 2 | 2 | 1 | 1 | 1 |
| Not completed | 0 | 1 | 2 | 2 | 1 |
| Withdrew: Study discontinued by sponsor | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-75 response rate is defined as at least 75 percent (%) reduction in PASI score relative to Baseline.
| % of subjects achieving PASI-75 | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT). | 0 | 0 | 0 | 0 | 0 |
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percent change was calculated by taking the Week 12 PASI score and subtracting the baseline PASI, and dividing by the baseline PASI, then multiplying by 100 to get the percent change from baseline.
| % change in PASI Score | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in PASI Score | -17.51 ± 3.120 | -27.69 ± 2.499 | -33.33 ± NA | -34.09 ± 33.429 | 0.00 ± NA |
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-50 response rate is defined as at least 50 percent (%) reduction in PASI score relative to Baseline.
| % of subjects achieving PASI-50 | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI) | 0 | 0 | 0 | 50 | 0 |
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-90 response rate is defined as at least 90 percent (%) reduction in PASI score relative to Baseline.
| % of subjects achieving PASI-90 | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI) | 0 | 0 | 0 | 0 | 0 |
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-100 response rate is defined as 100 percent (%) reduction in PASI score relative to Baseline.
| % of subjects achieving PASI-100 | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI) | 0 | 0 | 0 | 0 | 0 |
The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). For this outcome measure, a score of 0 means no symptoms of psoriasis and a score of 1 means minimal symptoms of psoriasis.
| % of subjects achieving sPGA 0 or 1 | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1 | 0 | 0 | 0 | 50 | 0 |
The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). Change from baseline to Week 12 in sPGA was calculated by taking the Week 12 sPGA and subtracting the baseline sPGA.
| score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Static Physician's Global Assessment (sPGA) Score | 0.0 ± 0.00 | -1.0 ± 0.00 | 0.0 ± NA | -1.5 ± 0.71 | 0.0 ± NA |
The total body surface area (BSA) affected by plaque-type psoriasis was obtained from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) and the resulting 4 values were added up to obtain the total psoriasis BSA (Range: 0 to 100). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region surface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs. Percent change from baseline to Week 12 in BSA was calculated by taking the Week 12 BSA and subtracting the baseline BSA, then dividing by the baseline BSA and multiplying by 100. A negative change from baseline at Week 12 indicates a reduction in the Psoriasis BSA compared to the baseline.
| % change in Psoriasis BSA | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Psoriasis Body Surface Area (BSA) | 0.00 ± 0.000 | -20.02 ± 12.099 | 0.00 ± NA | -0.36 ± 0.516 | 0.00 ± NA |
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Overall scale score is an average of 16 items expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Overall Score was calculated by taking the Week 12 Skindex-16 Overall Score and subtracting the baseline Skindex-16 Overall Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
| score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in the Skindex-16 Overall Score | -5.75 ± 15.486 | -14.10 ± 28.709 | -9.40 ± NA | -20.80 ± 20.648 | 6.20 ± NA |
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score is an average of items 1 to 4 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Symptoms Scale Score was calculated by taking the Week 12 Skindex-16 Symptoms Scale Score and subtracting the baseline Skindex-16 Symptoms Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
| score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in the Skindex-16 Symptoms Scale Score | 8.35 ± 0.071 | -14.60 ± 56.003 | -16.60 ± NA | -10.40 ± 14.708 | 16.60 ± NA |
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Emotions scale score is an average of items 5 to 11 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Emotions Scale Score was calculated by taking the Week 12 Skindex-16 Emotions Scale Score and subtracting the baseline Skindex-16 Emotions Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
| score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in the Skindex-16 Emotions Scale Score | -9.50 ± 0.000 | -14.30 ± 20.223 | -14.30 ± NA | -23.85 ± 33.729 | -2.40 ± NA |
Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Functioning scale score is an average of items 12 to 16 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Functioning Scale Score was calculated by taking the Week 12 Skindex-16 Functioning Scale Score and subtracting the baseline Skindex-16 Functioning Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.
| score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in the Skindex-16 Functioning Scale Score | -11.65 ± 49.427 | -13.35 ± 18.880 | 3.40 ± NA | -25.00 ± 7.071 | 10.00 ± NA |
Subjects in the Safety Population (13, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The study was terminated early as per the Sponsor decision. All randomized subjects were included in the Safety Population.
| Participants | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Number of subjects with TEAEs | 0 | 2 | 2 | 3 | 0 |
| Number of subjects with no TEAEs | 2 | 1 | 1 | 0 | 2 |
Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTE-051 in the subjects randomized to JTE-051 treatment groups.
| ng/mL | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg |
|---|---|---|---|---|
| JTE-051 Trough Plasma Concentrations | 184 ± 70.7 | 51 ± 72.1 | 377 ± NA | 203 ± 286.4 |
Collected over Up to 16 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JTE-051 50 mg | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| JTE-051 100 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| JTE-051 150 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| JTE-051 200 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Hypoaesthesia oralGastrointestinal disorders | 0/2 | 0/3 | 0/3 | 1/3 | 0/2 |
| Ear infectionInfections and infestations | 0/2 | 1/3 | 0/3 | 0/3 | 0/2 |
| GastroenteritisInfections and infestations | 0/2 | 1/3 | 0/3 | 0/3 | 0/2 |
| Gastrointestinal infectionInfections and infestations | 0/2 | 0/3 | 1/3 | 0/3 | 0/2 |
| Oral candidiasisInfections and infestations | 0/2 | 0/3 | 1/3 | 0/3 | 0/2 |
| Tooth abscessInfections and infestations | 0/2 | 1/3 | 0/3 | 0/3 | 0/2 |
| Blood creatine phosphokinase increasedInvestigations | 0/2 | 1/3 | 0/3 | 0/3 | 0/2 |
| Transaminases increasedInvestigations | 0/2 | 1/3 | 0/3 | 0/3 | 0/2 |
| Weight increasedInvestigations | 0/2 | 1/3 | 0/3 | 0/3 | 0/2 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 0/3 | 1/3 | 0/2 |
Baseline characteristics results are reported for the Safety Population consisting of the randomized subjects who receive at least one dose of the study drug and have at least one post-randomization safety data: 13 subjects.
| Age, Categorical(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 3 | 3 | 2 | 12 |
| >=65 years | 1 | 0 | 0 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 3 | 2 | 0 | 6 |
| Male | 1 | 3 | 0 | 1 | 2 | 7 |
| Ethnicity (NIH/OMB)(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 0 | 2 |
| Not Hispanic or Latino | 1 | 3 | 3 | 2 | 2 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 1 |
| White | 2 | 2 | 2 | 3 | 2 | 11 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Canada | 1 | 2 | 1 | 1 | 0 | 5 |
| United States | 1 | 1 | 2 | 2 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Oct 2018, 11 months.
Results were first posted in Aug 2021, 2 years 9 months after primary completion. A results delay was requested in Nov 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.